文献速递神经MRPET

胶质瘤疗效评估:经典陷阱、新型混杂因素与新兴影像工具

Glioma response assessment: Classic pitfalls, novel confounders, and emerging imaging tools.
PubMed 文献 · Br J Radiol · 2018-11-14

本文综述浸润性胶质瘤疗效评估中的经典陷阱与新型混杂因素:术后或放疗相关改变可类似疾病进展,糖皮质激素和抗血管生成药物可类似肿瘤缓解,免疫治疗可致数月内强化和水肿进行性增加;现代脑肿瘤疗效标准可减少部分陷阱,其余需先进MRI方法和新型PET示踪剂解决。

要点

  • 术后或放疗相关改变可类似胶质瘤进展,需结合现代脑肿瘤疗效标准判读。
  • 糖皮质激素和抗血管生成药物可类似肿瘤缓解,但未必真正抑制肿瘤生长或改善生存。
  • 免疫治疗可致炎性改变,表现为数月内强化和水肿进行性增加。

核心结论

  • 现代脑肿瘤疗效标准可减少部分胶质瘤疗效评估陷阱,其余陷阱需先进MRI方法和新型PET示踪剂才能完全解决,其作用未来将继续增长。

研究设计与样本

  • 综述,总结浸润性胶质瘤神经影像疗效评估中的经典陷阱、新型混杂因素和新兴影像工具。

关键影像表现/征象

  • 术后或放疗相关改变可类似疾病进展。
  • 糖皮质激素和抗血管生成药物可类似肿瘤缓解,但未必真正抑制肿瘤生长或改善患者生存。
  • 免疫治疗反应可致炎性改变,表现为数月内肿瘤强化和水肿进行性增加。

诊断标准与关键数值

  • 现代脑肿瘤疗效标准可减少或避免部分陷阱。
  • 先进MRI方法和新型PET示踪剂对解决部分陷阱有重要作用。

临床应用与阅片要点

  • 阅片和报告胶质瘤疗效时需识别术后或放疗相关改变可类似进展。
  • 需注意糖皮质激素和抗血管生成药物可类似缓解,但未必真正抑制肿瘤生长或改善生存。
  • 免疫治疗后可出现数月内强化和水肿进行性增加,需结合现代脑肿瘤疗效标准判读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Neuroimaging plays a pivotal role in the care of patients with infiltrating gliomas, in whom imaging changes are often the first indications of tumor response or progression. Unfortunately, evaluation of glioma response is often not straightforward, even for experienced radiologists. Post-surgical or radiation-related changes may mimic the appearance of disease progression, while medications such as corticosteroids and antiangiogenic agents may mimic tumor response without truly arresting tumor growth or improving patient survival. Immunotherapy response can result in inflammatory changes which manifest as progressively increasing tumor enhancement and edema over months. Many of these pitfalls can be minimized or avoided altogether by the use of modern brain tumor response criteria, while others will require new imaging tools before they can be fully addressed. Advanced MRI methods and novel positron emission tomography (PET) agents are proving important for this purpose, and their role will undoubtedly continue to grow in the future.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Johnson DR, Guerin JB, Ruff MW, et al. Glioma response assessment: Classic pitfalls, novel confounders, and emerging imaging tools. Br J Radiol. 2018. PMID: 30412421. doi:10.1259/bjr.20180730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。